Background: Activated V gamma V iota 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. Objective: We discuss the possibility that the intentional activation of gamma delta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. Methods: The antitumoural effects of gamma delta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. Results/conclusion: V gamma 9V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
Aminobisphosphonate-activated gamma delta T cells in immunotherapy of cancer: doubts no more / Caccamo, N; Meraviglia, S; Scarpa, F; La Mendola, C; Santini, D; Bonanno, Ct; Misiano, G; Dieli, F; Salerno, A. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 8:7(2008), pp. 875-883. [10.1517/14712590802102989]
Aminobisphosphonate-activated gamma delta T cells in immunotherapy of cancer: doubts no more
Santini D;
2008
Abstract
Background: Activated V gamma V iota 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. Objective: We discuss the possibility that the intentional activation of gamma delta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. Methods: The antitumoural effects of gamma delta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. Results/conclusion: V gamma 9V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
